News headlines about Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Verona Pharma PLC American Depositary Share earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.8960196549699 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) opened at 12.4028 on Friday. The stock’s market cap is $79.63 million. Verona Pharma PLC American Depositary Share has a 12 month low of $11.03 and a 12 month high of $50.88. The stock has a 50 day moving average price of $14.25 and a 200-day moving average price of $13.71.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.09. On average, analysts expect that Verona Pharma PLC American Depositary Share will post ($2.23) EPS for the current year.

A number of equities research analysts have commented on the company. Jefferies Group LLC reissued a “buy” rating and issued a $26.00 target price on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Wedbush assumed coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued an “outperform” rating and a $25.00 target price for the company. SunTrust Banks, Inc. assumed coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $26.00 target price for the company. Zacks Investment Research raised Verona Pharma PLC American Depositary Share from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Stifel Nicolaus assumed coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $22.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $22.60.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Verona Pharma PLC American Depositary Share (VRNA) Stock Price” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/20/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-verona-pharma-plc-american-depositary-share-vrna-stock-price.html.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Stock Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related stocks with our FREE daily email newsletter.